Let’s talk about that Lilly announcement
There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →
Our response to the op-ed in The Hill
The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →
The shortage ends … then what? (Find out at CCH)
We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →
A big welcome to Ro, APC’s newest tier-level corporate patron! read more →
For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →
At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →
503B sourcing: our state-by-state analysis
Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →
What we’ll be talking about at CCH
When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important. read more →
… (Read the rest)
CONTACT US
E-mail: info@a4pc.org
Phone: (281) 933-8400
Fax: (281) 495-0602
Mailing: Alliance for Pharmacy Compounding
100 Daingerfield Road, Ste. 100
Alexandria, VA 22314
APC is committed to addressing any concerns or complaints within one business day. Please send them — and, of course, any compliments — to info@a4pc.org.
THE APC FAMILY